LPL Financial LLC Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

LPL Financial LLC boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 18.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,741 shares of the specialty pharmaceutical company’s stock after buying an additional 2,029 shares during the period. LPL Financial LLC’s holdings in Supernus Pharmaceuticals were worth $461,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of SUPN. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $72,000. Venturi Wealth Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $92,000. KBC Group NV lifted its holdings in Supernus Pharmaceuticals by 53.1% in the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 929 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new stake in Supernus Pharmaceuticals in the 4th quarter worth approximately $211,000.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $32.22 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a market capitalization of $1.80 billion, a PE ratio of 30.11 and a beta of 0.90. The business has a 50 day simple moving average of $31.94 and a 200-day simple moving average of $34.97.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.